Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c